Analysis of expression kinetics and activity of a new B-domain truncated and full-length FVIII protein in three different cell lines

Annals of Hematology

Volumn 78, Issue 3, 1999, Pages 111-116

  Haack, A ^a   Schmitt, C ^a   Poller, W ^b   Oldenburg, J ^c   Hanfland, P ^a   Brackmann, H H ^a   Schwaab, R ^a  

^a UNIVERSITY OF BONN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

B domain; Cell type specific; FVIII; Specific activity; Transient expression

Indexed keywords

BLOOD CLOTTING FACTOR 8; MUTANT PROTEIN; RECOMBINANT PROTEIN;

ANIMAL CELL; ARTICLE; ASSAY; CELL LINE; CELL STRAIN COS1; CHO CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; KINETICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; CELL LINE; CHO CELLS; COS CELLS; CRICETINAE; EMBRYO; FACTOR VIII; GENE EXPRESSION; HUMANS; KIDNEY; KINETICS; PROTEIN ENGINEERING; RECOMBINANT PROTEINS; SEQUENCE DELETION; TRANSFECTION; VON WILLEBRAND FACTOR;

EID: 0032970591     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002770050486     Document Type: Article

References (35)

1. Alwine JC (1985) Transient gene expression control: effects of transfected DNA stability and trans-activation by viral early proteins. Mol Cell Biol 5:1034-1042
2. Aly AM, Higuchi M, Kasper CK, Kazazian HH jr, Antonarakis SE, Hoyer LW (1992) Hemophilia A due to mutations that create new N-glycosylation sites. Proc Natl Acad Sci U S A 89:4933-4937
3. Berkner KL (1992) Expression of heterologous sequences in adenoviral vectors. Curr Top Microbiol Immunol 158:39-67
4. Cumming DA (1991) Glycosylation of recombinant protein therapeutics: control and functional implications. Glycobiology 1:115-130
5. Dawson NJ, Kemball-Cook G, Barrowcliffe TW (1989) Assay discrepancies with highly purified factor VIII concentrates. Haemostasis 19:131-137
6. Dorner AJ, Bole DG, Kaufman RJ (1987) The relationship of N-linked glycosylation and heavy chain-binding protein association with the secretion of glycoproteins. J Cell Biol 105:2665-2674
7. Eaton DL, Wood EI, Eaton D, Hass PE, Hollingshead P, Wion K, Mather J, Lawn RM, Vehar GA, Gorman C, (1986) Construction and characterization of an active factor VIII variant lacking the central one third of the molecule. Biochemistry 25:8343-8347
8. Egli H (1968) Laboratoriumsdiagnostik der Hämophilen. Deu Med J 14:495-499
9. Fijnavandraat K, Berntrop E, ten Cate JW, Johnsson H, Peters M, Savidge G, Tengbor L, Spira J, Stahl C (1997) Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients. Thromb Haemost 77:298-302
10. Goochee CF, Monica T (1990) Environmental effects on protein glycosylation. Biotechnology 8:421-427
11. Goochee CF, Gramer MJ, Andersen DC, Bahr JB. Rasmussen JR (1991) The oligosaccharides of glycoproteins: bioprocess factors affecting oligosaccharide structure and their effect on glycoprotein properties. Biotechnology 9:1347-1355
12. Graham FL, Smiley J, Russell WC and Nairn R (1977) Characteristics of a human cell line transformed by DNA from human adenovirus 5. J Gen Virol 36:59-72
13. Hellenstern P, Kiehl R, Miyashita C, Schwerdt H, Blohn G v, Köhler M, Büttner M, Wenzel E (1986) Factor VIII:C (FVIII:C) recovery and half-life after infusion of steam-treated high purity factor VIII concentrate in severe hemophilia A - comparison of one-stage assay, two-stage assay and a chromogenic substrate assay. Thromb Haemost 56:353-359
14. Hironaka T, Furukawa K, Esmon PC, Fournel MA, Sawada S, Kato M, Minaga T, Kobata A (1992) Comparative study of the sugar chains of factor VIII purified from human plasma and from the culture media of recombinant baby hamster kidney cells. J Biol Chem 267:8012-8020
15. Hironaka T, Furukawa K, Esmon PC, Yokota T, Brown JE, Sawada S, Fournel MA, Kato M, Minaga T, Kobata A (1993) Structural study of the sugar chains of porcine factor VIII-tissue-and species-specific glycosylation of factor VIII. Arch Biochcm Biophys 307:316-330
16. Hoyer LW (1994) Hemophilia A. N Engl J Med 330:38-47
17. Kaufman RJ, Pipe SW, Shah J (1997) Secretion of coagulation factor VIII requires interaction with the protein chaperone calnexin and is limited by intracellular degradation via the ubiquitin-proteasomal pathway. Thromb Haemost [Suppl]: PS 2557
18. Kaufman RJ, Wasley LC, Dorner AJ (1988) Synthesis, processing and secretion of recombinant human factor VIII expressed in mammalian cells. J Biol Chem 263:6352-62
19. Kaufman RJ, Wasley LC, Davies MV, Wise RJ, Israel DI, Dorner AJ (1989) Effect of von Willebrand factor coexpression on the synthesis and secretion of factor VIII in Chinese hamster ovary cells. Mol Cell Biol 9:1233-1242
20. Kaufman RJ (1992) Biological regulation of factor VIII activity. Annu Rev Med 43:325-339
21. Kaufman RJ (1992) Expression and structure-function properties of recombinant factor VIII. Transfus Med Rev 6:235-246
22. Koch A, Tonn JA, Kraus JA, Sörensen N, Albrecht S, Wiestler OD, Pietsch T (1996) Molecular analysis of the lissencephaly gene 1 (lis-1) in meduloblastomas. Neuropathol Appl Neurobiol 22:233-242
23. Kumar HPM, Hague C, Haley T, Starr CM, Besman MJ, Lundblad RL, Baker D (1996) Elucidation of N-linked oligosaccharide structure of recombinant human FVIII using fluoreassisted carbohydrate electrophoresis. Biotechnol Appl Biochem 24:207-216
24. Marquette KA, Pittman DD, Kaufman RJ (1995) A 110-amino acid region within the A1-domain of coagulation factor VIII inhibits secretion fram mammalian cells. J Biol Chem 270:10297-10303
25. Meulien P, Faure T, Mischler F, Harrer H, Ulrich P, Bouderbala B, Dott K, Marie MS, Mazurier C, Wiesel M-L, Van de Pol H, Cazenave J-P, Courtney M, Pavirani (1988) A new recombinant procoagulation protein derived from the cDNA encoding human factor VIII. Protein Eng 2:301-306
26. Mikaelsson M, Oswaldsson U, Nilsson IM (1994) Potency and in vivo recovery of high purity factor VIII concentrates (letter). Thromb Haemost 72:160-161
27. Pittman DD, Alderman EM, Tomkinson KN, Wang JH, Giles AR, Kaufman RJ (1993) Biochemical, immunological and in vivo functional characterization of B-domain deleted factor VIII. Blood 81:2925-2935
28. Pittman DD, Marquette KA, Kaufman RJ (1994) Role of the B-domain for factor VIII and factor V expression and function. Blood 84:4214-4225
29. Pittman DD, Tomkinson KN, Kaufman RJ (1994) Post-translational requirements for functional factor V and factor VIII secretion in mammalian cells. J Biol Chem 269, 25:17329-17337
30. Sarver N, Ricca GA, Link J, Nathan MH, Newman J, Drohan WN (1987) Stable expression of recombinant factor VIII molecules using a bovine papillomavirus vector. DNA 6:553-564
31. Schmitt C, Oldenburg J, Haack A, Poller W, Brackmann HH, Schwaab R (1997) Investigation of factor VIII-antigen levels of patients with haemophilia A by a new highly sensitive enzyme linked immunosorbent assay (ELISA). Thromb Haemost [Suppl]: PS 120
32. Toole JJ, Knopf JL, Woznwy JM, Sultzman LA, Buecker JL, Pittman DD, Kaufman RJ, Brown E, Shoemaker C, Orr EC, Amphlett GW, Foster WB, Coe LM, Knutson GJ, Fass DN, Hewick RM (1984) Molecular cloning of a cDNA encoding human anithaemophilic factor. Nature 312:342-347
33. Toole JJ, Pittman DD, Orr EC, Murtha P, Wasley LC, Kaufman RJ (1986) A large region (ca. 95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity. Proc Natl Acad Sci U S A 83:5939-5942
34. Vehar GA, Keyt B, Eaton D, Rodriguez H, O'Brien DP, Rotblat F, Oppermann H, Keck R, Wood IW, Harkins RN, Tuddenham EGD, Lawn RM, Capon DJ (1984) Structure of human factor VIII. Nature 312:337-342
35. Wood IW, Capon DJ, Simonsen CC, Eaton DL, Gitschier J, Keyt B, Seeburg HP, Smith HD, Hollingshead P, Wion KL, Delwart E, Tuddenham EGD, Vehar G, Lawn RM (1984) Expression of active human factor VIII from recombinant DNA clones. Nature 312:330-337